{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:47:10Z","timestamp":1790948830960,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06431-w","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T23:20:39Z","timestamp":1748388039000},"page":"3103-3115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of secondary-type mutations on the prognosis of AML patients with NPM1 mutation: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Tao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1174-4078","authenticated-orcid":false,"given":"Hongbing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"6431_CR1","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6:e441","journal-title":"Blood Cancer J"},{"key":"6431_CR2","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC (2016) Acute myeloid leukaemia. Nat Rev Dis Primers 2:16010","journal-title":"Nat Rev Dis Primers"},{"key":"6431_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O\u2019Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Dohner K, Schlenk RF, Dohner H, Campbell PJ (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209\u20132221","journal-title":"N Engl J Med"},{"key":"6431_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-22-3631","volume":"83","author":"KR Sekhar","year":"2023","unstructured":"Sekhar KR, Freeman ML (2023) Nucleophosmin plays a role in repairing DNA damage and is a target for Cancer treatment. Cancer Res 83:1573\u20131580","journal-title":"Cancer Res"},{"key":"6431_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12867-016-0073-9","volume":"17","author":"JK Box","year":"2016","unstructured":"Box JK, Paquet N, Adams MN, Boucher D, Bolderson E (2016) O\u2019Byrne KJ and Richard DJ. Nucleophosmin: from structure and function to disease development. BMC Mol Biol 17:19","journal-title":"BMC Mol Biol"},{"key":"6431_CR6","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, Brunetti L, Sportoletti P, Martelli MP (2020) NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood 136:1707\u20131721","journal-title":"Blood"},{"key":"6431_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","volume":"13","author":"XQD Wang","year":"2023","unstructured":"Wang XQD, Fan D, Han Q, Liu Y, Miao H, Wang X, Li Q, Chen D, Gore H, Himadewi P, Pfeifer GP, Cierpicki T, Grembecka J, Su J, Chong S, Wan L, Zhang X (2023) Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia. Cancer Discov 13:724\u2013745","journal-title":"Cancer Discov"},{"key":"6431_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41408-023-00898-4","volume":"13","author":"I Khan","year":"2023","unstructured":"Khan I, Kaempf A, Raghuwanshi S, Chesnokov M, Zhang X, Wang Z, Domling A, Tyner JW, Camacho C, Gartel AL (2023) Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance. Blood Cancer J 13:128","journal-title":"Blood Cancer J"},{"key":"6431_CR9","doi-asserted-by":"publisher","first-page":"972606","DOI":"10.3389\/fonc.2022.972606","volume":"12","author":"R Wang","year":"2022","unstructured":"Wang R, Xu P, Chang LL, Zhang SZ, Zhu HH (2022) Targeted therapy in NPM1-mutated AML: knowns and unknowns. Front Oncol 12:972606","journal-title":"Front Oncol"},{"key":"6431_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1182\/bloodadvances.2023011173","volume":"8","author":"O Chan","year":"2024","unstructured":"Chan O, Al Ali N, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini M, Song J, Yun S, Talati C, Kuykendall A, Padron E, Walker A, Roboz G, Desai P, Sallman D, Sweet K (2024) Komrokji R and lancet J. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv 8:1075\u20131083","journal-title":"Blood Adv"},{"key":"6431_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-019-0268-7","volume":"10","author":"LH Xu","year":"2020","unstructured":"Xu LH, Fang JP, Liu YC, Jones AI, Chai L (2020) Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia. Blood Cancer J 10:1","journal-title":"Blood Cancer J"},{"key":"6431_CR12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367\u20131376","journal-title":"Blood"},{"key":"6431_CR13","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W (2022) Yeung C and Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia; 36: 1703\u20131719","DOI":"10.1038\/s41375-022-01613-1"},{"key":"6431_CR14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3324\/haematol.2017.181842","volume":"103","author":"OK Weinberg","year":"2018","unstructured":"Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP (2018) Association of mutations with morphological dysplasia in de Novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 103:626\u2013633","journal-title":"Haematologica"},{"key":"6431_CR15","doi-asserted-by":"crossref","unstructured":"Sharma N, Liesveld JL (2023) NPM 1 mutations in AML-The landscape in 2023. Cancers (Basel); 15","DOI":"10.3390\/cancers15041177"},{"key":"6431_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J (2022) Wierzbowska A and Lowenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377","journal-title":"Blood"},{"key":"6431_CR17","doi-asserted-by":"publisher","first-page":"E462","DOI":"10.1002\/ajh.26730","volume":"97","author":"MF Wright","year":"2022","unstructured":"Wright MF, Pozdnyakova O, Hasserjian RP, Aggarwal N, Shaver AC, Weinberg OK, Irlmeier R, Koyama T, Seegmiller AC, Strickland SA, Mason EF (2022) Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1. Am J Hematol 97:E462\u2013E465","journal-title":"Am J Hematol"},{"key":"6431_CR18","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1038\/s41375-023-02016-6","volume":"37","author":"JN Eckardt","year":"2023","unstructured":"Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brummendorf TH, Krug U, Wormann B, Hiddemann W, Gorlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schafer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hanel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Muller-Tidow C, Bornhauser M, Herold T, Thiede C, Rollig C (2023) Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification. Leukemia 37:2282\u20132285","journal-title":"Leukemia"},{"key":"6431_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16","journal-title":"Trials"},{"key":"6431_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605","journal-title":"Eur J Epidemiol"},{"key":"6431_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","volume":"40","author":"AK Jayavelu","year":"2022","unstructured":"Jayavelu AK, Wolf S, Buettner F, Alexe G, Haupl B, Comoglio F, Schneider C, Doebele C, Fuhrmann DC, Wagner S, Donato E, Andresen C, Wilke AC, Zindel A, Jahn D, Splettstoesser B, Plessmann U, Munch S, Abou-El-Ardat K, Makowka P, Acker F, Enssle JC, Cremer A, Schnutgen F, Kurrle N, Chapuy B, Lober J, Hartmann S, Wild PJ, Wittig I, Hubschmann D, Kaderali L, Cox J, Brune B, Rollig C, Thiede C, Steffen B, Bornhauser M, Trumpp A, Urlaub H, Stegmaier K, Serve H, Mann M, Oellerich T (2022) The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 40:301\u2013317 e312","journal-title":"Cancer Cell"},{"key":"6431_CR22","doi-asserted-by":"publisher","first-page":"e70102","DOI":"10.1002\/cam4.70102","volume":"13","author":"Q Wu","year":"2024","unstructured":"Wu Q, Zhang Y, Yuan B, Huang Y, Jiang L, Liu F, Yan P, Cheng J, Long Z, Jiang X (2024) Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients. Cancer Med 13:e70102","journal-title":"Cancer Med"},{"key":"6431_CR23","doi-asserted-by":"publisher","first-page":"106869","DOI":"10.1016\/j.leukres.2022.106869","volume":"118","author":"D Zhao","year":"2022","unstructured":"Zhao D, Zarif M, Eladl E, Capo-Chichi JM, Smith AC, Atenafu EG, Tierens A, Minden MD, Schuh A, Chang H (2022) NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS\/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1. Leuk Res 118:106869","journal-title":"Leuk Res"},{"key":"6431_CR24","doi-asserted-by":"crossref","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, Burke R, Carlos A, Chang BH, Cho HJ, Christy S, Coblentz C, Cohen AM, d\u2019Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Dibb J, Eide CA, English I, Hagler S, Harrelson H, Henson R, Ho H, Joshi SK, Junio B, Kaempf A, Kosaka Y, Laderas T, Lawhead M, Lee H, Leonard JT, Lin C, Lind EF, Liu SQ, Lo P, Loriaux MM, Luty S, Maxson JE, Macey T, Martinez J, Minnier J, Monteblanco A, Mori M, Morrow Q, Nelson D, Ramsdill J, Rofelty A, Rogers A, Romine KA, Ryabinin P, Saultz JN, Sampson DA, Savage SL, Schuff R, Searles R, Smith RL, Spurgeon SE, Sweeney T, Swords RT, Thapa A, Thiel-Klare K, Traer E, Wagner J, Wilmot B, Wolf J, Wu G, Yates A, Zhang H, Cogle CR, Collins RH, Deininger MW, Hourigan CS, Jordan CT, Lin TL, Martinez ME, Pallapati RR, Pollyea DA, Pomicter AD, Watts JM, Weir SJ, Druker BJ (2022) McWeeney SK and Tyner JW. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell; 40: 850\u2013864 e859","DOI":"10.1016\/j.ccell.2022.07.002"},{"key":"6431_CR25","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.2024024310","volume":"144","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes A, Gale R, Rapoz-D\u2019Silva T, Runglall M, Kleeman M, Dhami P, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Huntly B (2024) Russell NH and Dillon R. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood 144:714\u2013728","journal-title":"Blood"},{"key":"6431_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/ejh.13979","volume":"111","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Zhao D, Zarif M, Yeung YWT, Richard-Carpentier G, Chang H (2023) Impact of secondary-type mutations in NPM1 mutated AML. Eur J Haematol 111:165\u2013168","journal-title":"Eur J Haematol"},{"key":"6431_CR27","doi-asserted-by":"crossref","unstructured":"Wang Y, Quesada AE, Zuo Z, Medeiros LJ, Yin CC, Li S, Xu J, Borthakur G, Li Y, Yang C, Abaza Y, Gao J, Lu X, You MJ, Zhang Y, Lin P (2022) The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. Cancers (Basel).; 15","DOI":"10.3390\/cancers15010198"},{"key":"6431_CR28","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Leppa AM, Renders S, Stumpf K, Reyneri C, Betz B, Janssen M, Shahswar R, Donato E, Karpova D, Thiel V, Unglaub JM, Grabowski S, Gryzik S, Vierbaum L, Schlenk RF, Rollig C, Hundemer M, Pabst C, Heuser M, Raffel S, Muller-Tidow C, Sauer T, Trumpp A (2023) Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to Azacitidine\/Venetoclax. Cancer Discov 13:1408\u20131427","journal-title":"Cancer Discov"},{"key":"6431_CR29","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1182\/blood-2023-185566","volume":"142","author":"S Cocciardi","year":"2023","unstructured":"Cocciardi S, Wei\u00df N, Saadati M, Skambraks S, Weber D, Schneider I, Meid A, Aicher S, Bengesser-Kuhn K, Corbacioglu A, Gaidzik VI, Theis F, Fiedler W, K\u00fchn M, Germing U, Mayer KT, L\u00fcbbert M, Thol F, Heuser M, Ganser A, Bullinger L, Benner A (2023) D\u00f6hner H and D\u00f6hner K. The genomic landscape and its clinical implication in NPM1-Mutated AML patients: A study within the AMLSG 09\u201309 clinical trial. Blood 142:4311\u20134311","journal-title":"Blood"},{"key":"6431_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","volume":"7","author":"GC Issa","year":"2023","unstructured":"Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N (2023) Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7:933\u2013942","journal-title":"Blood Adv"},{"key":"6431_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2022-168522","volume":"140","author":"MY Lo","year":"2022","unstructured":"Lo MY, Tsai C-H, Kuo Y-Y, Tseng M-H, Peng Y-L, Hsu C-A, Sun H-I, Chuang Y-K, Chou W-C (2022) Hou H-A and Tien H-F. Prognostic relevance of adult acute myeloid leukemia patients according to the 2022 European leukemianet risk stratification. Blood 140:130\u2013131","journal-title":"Blood"},{"key":"6431_CR32","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1182\/blood-2022-171197","volume":"140","author":"O Chan","year":"2022","unstructured":"Chan O, Al Ali N, Ball S, Grenet J, Hana C, Deutsch YE, Tashkandi H, Zhang L, Hussaini MO, Yun S, Kuykendall A, Padron E, Roboz GJ, Desai P, Komrokji RS, Sweet K, Lancet JE, Sallman DA (2022) The prognostic impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD confers poor outcomes. Blood 140:3435\u20133437","journal-title":"Blood"},{"key":"6431_CR33","doi-asserted-by":"crossref","unstructured":"Borlenghi E, Cattaneo C, Bertoli D, Cerqui E, Archetti S, Passi A, Oberti M, Zollner T, Giupponi C, Pagani C, Bianchetti N, Bottelli C, Bagnasco S, Sciume M, Tucci A, Rossi G (2022) Prognostic relevance of NPM1 and FLT3 mutations in acute myeloid leukaemia, longterm Follow-Up-A single center experience. Cancers (Basel); 14","DOI":"10.3390\/cancers14194716"},{"key":"6431_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood.2019000942","volume":"136","author":"AJ Menssen","year":"2020","unstructured":"Menssen AJ, Walter MJ (2020) Genetics of progression from MDS to secondary leukemia. Blood 136:50\u201360","journal-title":"Blood"},{"key":"6431_CR35","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","volume":"5","author":"D Luque Paz","year":"2021","unstructured":"Luque Paz D, Riou J, Verger E, Cassinat B, Chauveau A, Ianotto JC, Dupriez B, Boyer F, Renard M, Mansier O, Murati A, Rey J, Etienne G, Mansat-De Mas V, Tavitian S, Nibourel O, Girault S, Le Bris Y, Girodon F, Ranta D, Chomel JC, Cony-Makhoul P, Sujobert P, Robles M, Ben Abdelali R, Kosmider O, Cottin L, Roy L, Sloma I, Vacheret F, Wemeau M, Mossuz P, Slama B, Cussac V, Denis G, Walter-Petrich A, Burroni B, Jezequel N, Giraudier S, Lippert E, Socie G, Kiladjian JJ, Ugo V (2021) Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv 5:1442\u20131451","journal-title":"Blood Adv"},{"key":"6431_CR36","doi-asserted-by":"crossref","unstructured":"Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T (2020) EZH2 in Myeloid Malignancies. Cells; 9","DOI":"10.3390\/cells9071639"},{"key":"6431_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-022-01336-x","volume":"15","author":"EA Medina","year":"2022","unstructured":"Medina EA, Delma CR, Yang FC (2022) ASXL1\/2 mutations and myeloid malignancies. J Hematol Oncol 15:127","journal-title":"J Hematol Oncol"},{"key":"6431_CR38","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","volume":"4","author":"AL Brown","year":"2020","unstructured":"Brown AL, Arts P, Carmichael CL, Babic M, Dobbins J, Chong CE, Schreiber AW, Feng J, Phillips K, Wang PPS, Ha T, Homan CC, King-Smith SL, Rawlings L, Vakulin C, Dubowsky A, Burdett J, Moore S, McKavanagh G, Henry D, Wells A, Mercorella B, Nicola M, Suttle J, Wilkins E, Li XC, Michaud J, Brautigan P, Cannon P, Altree M, Jaensch L, Fine M, Butcher C, D\u2019Andrea RJ, Lewis ID, Hiwase DK, Papaemmanuil E, Horwitz MS, Natsoulis G, Rienhoff HY, Patton N, Mapp S, Susman R, Morgan S, Cooney J, Currie M, Popat U, Bochtler T, Izraeli S, Bradstock K, Godley LA, Kramer A, Frohling S, Wei AH, Forsyth C, Mar Fan H, Poplawski NK (2020) Hahn CN and Scott HS. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv 4:1131\u20131144","journal-title":"Blood Adv"},{"key":"6431_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-981-10-3233-2_17","volume":"962","author":"RK Hyde","year":"2017","unstructured":"Hyde RK, Liu P, Friedman AD (2017) RUNX1 and CBFbeta mutations and activities of their Wild-Type alleles in AML. Adv Exp Med Biol 962:265\u2013282","journal-title":"Adv Exp Med Biol"},{"key":"6431_CR40","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/ajcp\/aqad077","volume":"160","author":"J Tatarian","year":"2023","unstructured":"Tatarian J, Tupper N, Li P, Feusier J, Abdo M, Hyter S, Gonzales PR, Zhang D, Woodroof J, Kelting S, Godwin AK, Cui W (2023) Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia. Am J Clin Pathol 160:490\u2013499","journal-title":"Am J Clin Pathol"},{"key":"6431_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3324\/haematol.2022.280765","volume":"108","author":"M Othus","year":"2023","unstructured":"Othus M, Garcia-Manero G, Godwin JE, Weick JK, Appelbaum FR, Erba HP, Estey EH (2023) Improved outcomes with 7\u2009+\u20093 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. Haematologica 108:42\u201347","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06431-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06431-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06431-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:59:17Z","timestamp":1757174357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06431-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6431"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06431-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}